Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

199
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
199
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.6K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

508
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
508

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same author

A nationwide multi-centre survey of 12,500 cases of upper gastrointestinal bleeding: A report of Indian Society of Gastroenterology Task Force on acute upper gastrointestinal bleed.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.

Nature communications·2026
Same author

Author Correction: Nutrient-sensing nuclear receptors coordinate autophagy.

Nature·2026
Same author

Proteomic and Lipidomic Atlas of Gut-Associated Lymph and Venous Depots in Female Piglets.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN.

Hepatology (Baltimore, Md.)·2025

Related Experiment Video

Updated: Jan 10, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

1.9K

Elevated copper impairs hepatic nuclear receptor function in Wilson's disease.

Clavia Ruth Wooton-Kee, Ajay K Jain, Martin Wagner

    The Journal of Clinical Investigation
    |August 5, 2015
    PubMed
    Summary

    Wilson's disease (WD) causes copper buildup in the liver, impairing nuclear receptors and disrupting liver function. This copper toxicity affects liver health in WD patients and similar conditions.

    More Related Videos

    Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
    11:04

    Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

    Published on: September 7, 2019

    9.7K
    The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
    07:27

    The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

    Published on: October 21, 2017

    12.3K

    Related Experiment Videos

    Last Updated: Jan 10, 2026

    Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
    06:52

    Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

    Published on: April 28, 2023

    1.9K
    Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
    11:04

    Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

    Published on: September 7, 2019

    9.7K
    The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
    07:27

    The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

    Published on: October 21, 2017

    12.3K

    Area of Science:

    • Hepatology
    • Molecular Biology
    • Genetics

    Background:

    • Wilson's disease (WD) is an inherited liver disorder caused by ATP7B gene mutations, leading to toxic copper accumulation.
    • Copper overload in WD patients and Atp7b⁻/⁻ mice causes significant liver pathology, including steatosis, cholestasis, cirrhosis, and liver failure.
    • Previous research indicates copper can interfere with nuclear receptor function, impacting gene regulation.

    Purpose of the Study:

    • To investigate the impact of hepatic copper accumulation on nuclear receptor activity in Wilson's disease.
    • To determine if copper-mediated nuclear receptor dysfunction contributes to liver pathology in WD.
    • To explore the role of impaired nuclear receptor activity in other conditions with high hepatic copper, such as progressive familial cholestasis (PFIC).

    Main Methods:

    • Assessed nuclear receptor binding to DNA response elements in Atp7b⁻/⁻ mice and human WD patients (adults and children).
    • Measured mRNA expression of nuclear receptor target genes in affected mice and patients.
    • Examined nuclear receptor activity in patients with PFIC2 and PFIC3, conditions characterized by elevated hepatic copper.

    Main Results:

    • Found decreased binding of key nuclear receptors (FXR, RXR, HNF4α, LRH-1) to promoter elements in Atp7b⁻/⁻ mice and WD patients.
    • Observed reduced mRNA expression of nuclear receptor target genes in both mouse models and human WD cohorts.
    • Demonstrated impaired nuclear receptor activity in PFIC2 and PFIC3 patients, correlating with high hepatic copper levels.

    Conclusions:

    • Copper accumulation in Wilson's disease directly impairs the function of critical nuclear receptors, including FXR, RXR, HNF4α, and LRH-1.
    • This copper-mediated nuclear receptor dysfunction is a key mechanism contributing to liver damage and functional impairment in Wilson's disease.
    • The findings suggest that impaired nuclear receptor activity due to copper overload may also play a role in other liver diseases like PFIC, highlighting a common pathway.